<p>都柏林 --（商業資訊）--Prothena Corporation plc（納斯達克：PRTA）是一家處於後期臨牀階段的生物技術公司，擁有基於蛋白質失調專業知識的強大研發管線，今天宣佈 Paula Cobb 將辭去 Prothena 董事會職務，加入 Manifold Bio 擔任首席運營官。在她六年的任期內，Cobb 女士在公司願景和戰略方面做出了重要貢獻。</p>
<p>“我想感謝 Paula 在過去六年中的諸多貢獻。作為一名擁有廣泛全球開發、商業戰略和商業專業知識的生物技術高管，她為董事會和領導層提供了寶貴的見解，” Prothena 董事會主席 Daniel G. Welch 表示。“整個董事會都非常感謝 Paula 自 2019 年加入董事會以來的戰略專業知識和影響力，並祝願她在新角色中繼續取得成功。”</p>
<p>“在過去六年中，我很榮幸能在 Prothena 董事會任職，” Cobb 表示。“我為我們共同取得的成就感到自豪，並對公司開發變革性藥物以治療因蛋白質失調而遭受嚴重疾病的患者的戰略願景充滿信心。”</p>
<p>隨着 Cobb 女士的離職，Prothena 董事會現有 8 名董事。</p>
<p><strong>關於 Prothena</strong></p>
<p>Prothena Corporation plc 是一家處於後期臨牀階段的生物技術公司，專注於蛋白質失調，擁有一系列具有潛力改變嚴重神經退行性疾病和罕見外周澱粉樣病的研發藥物。憑藉數十年研究積累的深厚科學專業知識，Prothena 正在推進一系列治療候選藥物，針對多種適應症和新靶點，利用其在神經功能障礙和錯誤摺疊蛋白生物學方面的科學見解。Prothena 的管線包括完全擁有和合作開發的項目，旨在潛在治療包括伴有心肌病的 ATTR 澱粉樣變、阿爾茨海默病、帕金森病以及其他多種神經退行性疾病。有關更多信息，請訪問公司網站 www.prothena.com，並在 X（前身為 Twitter）上關注公司 @ProthenaCorp。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2NzU3NDdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2NzU3NDdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212675747/en/</p>
<p>Mark Johnson, CFA</p>
<p>投資者關係副總裁</p>
<p>650-837-8550</p>
<p>IR@prothena.com</p>
<p>Media@prothena.com</p>
<p>來源：Prothena Corporation plc</p>

PRTA

<p>Prothena Corporation 宣佈 Paula Cobb 將辭去董事會職務，加入 Manifold Bio 擔任首席運營官。Cobb 在 Prothena 任職六年期間對公司的願景和戰略做出了重要貢獻。董事會對她的戰略專長表示感謝，並祝願她在新職位上取得成功。Prothena 目前董事會成員共有 8 位</p>

<p>DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena’s Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company’s vision and strategy.</p>
<div class="lb-trans"><p>都柏林 --（商業資訊）--Prothena Corporation plc（納斯達克：PRTA）是一家處於後期臨牀階段的生物技術公司，擁有基於蛋白質失調專業知識的強大研發管線，今天宣佈 Paula Cobb 將辭去 Prothena 董事會職務，加入 Manifold Bio 擔任首席運營官。在她六年的任期內，Cobb 女士在公司願景和戰略方面做出了重要貢獻。</p>
</div><p>“I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and leadership,” said Daniel G. Welch, Chair of Prothena’s Board of Directors. “The entire board of directors appreciates Paula’s strategic expertise and impact since joining the board in 2019 and we wish her continued success in her new role.”</p>
<div class="lb-trans"><p>“我想感謝 Paula 在過去六年中的諸多貢獻。作為一名擁有廣泛全球開發、商業戰略和商業專業知識的生物技術高管，她為董事會和領導層提供了寶貴的見解，” Prothena 董事會主席 Daniel G. Welch 表示。“整個董事會都非常感謝 Paula 自 2019 年加入董事會以來的戰略專業知識和影響力，並祝願她在新角色中繼續取得成功。”</p>
</div><p>“I have been honored to serve on the Prothena Board during these past six years,” said Cobb. “I am proud of what we accomplished together and remain confident in the company’s strategic vision to develop transformative medicines for patients suffering from devasting diseases caused by protein dysregulation.”</p>
<div class="lb-trans"><p>“在過去六年中，我很榮幸能在 Prothena 董事會任職，” Cobb 表示。“我為我們共同取得的成就感到自豪，並對公司開發變革性藥物以治療因蛋白質失調而遭受嚴重疾病的患者的戰略願景充滿信心。”</p>
</div><p>With the departure of Ms. Cobb, Prothena has 8 Directors on its board.</p>
<div class="lb-trans"><p>隨着 Cobb 女士的離職，Prothena 董事會現有 8 名董事。</p>
</div><p><strong>About Prothena</strong></p>
<div class="lb-trans"><p><strong>關於 Prothena</strong></p>
</div><p>Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.</p>
<div class="lb-trans"><p>Prothena Corporation plc 是一家處於後期臨牀階段的生物技術公司，專注於蛋白質失調，擁有一系列具有潛力改變嚴重神經退行性疾病和罕見外周澱粉樣病的研發藥物。憑藉數十年研究積累的深厚科學專業知識，Prothena 正在推進一系列治療候選藥物，針對多種適應症和新靶點，利用其在神經功能障礙和錯誤摺疊蛋白生物學方面的科學見解。Prothena 的管線包括完全擁有和合作開發的項目，旨在潛在治療包括伴有心肌病的 ATTR 澱粉樣變、阿爾茨海默病、帕金森病以及其他多種神經退行性疾病。有關更多信息，請訪問公司網站 www.prothena.com，並在 X（前身為 Twitter）上關注公司 @ProthenaCorp。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2NzU3NDdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251212675747r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251212675747/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212675747/en/</p>
</div><p>Mark Johnson, CFA</p>
<div class="lb-trans"><p>Mark Johnson, CFA</p>
</div><p>Vice President, Investor Relations</p>
<div class="lb-trans"><p>投資者關係副總裁</p>
</div><p>650-837-8550</p>
<div class="lb-trans"><p>650-837-8550</p>
</div><p>IR@prothena.com</p>
<div class="lb-trans"><p>IR@prothena.com</p>
</div><p>Media@prothena.com</p>
<div class="lb-trans"><p>Media@prothena.com</p>
</div><p>Source: Prothena Corporation plc</p>
<div class="lb-trans"><p>來源：Prothena Corporation plc</p>
</div>

Prothena 宣佈董事會更新 | PRTA 股票新聞